167 related articles for article (PubMed ID: 18511113)
1. Successful treatment with VAD of a myelodysplastic syndrome occurring during the course of a smoldering multiple myeloma.
Cortesão E; Espadana A; Laranjeiro P; Jara M; Orfão A
Leuk Res; 2009 Jan; 33(1):195-7. PubMed ID: 18511113
[No Abstract] [Full Text] [Related]
2. Chemotherapy of resistant multiple myeloma with vincristine, adriamycin and dexamethasone (VAD).
Maniatis A; Stamatellou M; Papanastasiou K
Chemioterapia; 1987 Jun; 6(2 Suppl):727-8. PubMed ID: 3509532
[No Abstract] [Full Text] [Related]
3. [Improved prognosis of generalized AL-amyloidosis in a patient with multiple myeloma treated according to the VAD protocol].
Sarkisova IA; Rameev VV; Kozlovskaia LV; Andreeva NE
Ter Arkh; 2003; 75(8):81-2. PubMed ID: 14520860
[No Abstract] [Full Text] [Related]
4. [VAD chemotherapy of multiple myeloma].
Amano M; Itoh K; Togawa A
Rinsho Ketsueki; 1990 Jul; 31(7):917-21. PubMed ID: 2214189
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of multiple myeloma resistant to alkylating agents with dexamethasone, vincristine and adriamycin in continuous infusion].
Monconduit M; Le Loët X; Bernard JF; Menard JF; Grosbois B; Michaux JL; De Gramont A; Laporte JP; Najman A; Jouet JP
Rev Rhum Mal Osteoartic; 1987 Jun; 54(6):477-9. PubMed ID: 3616472
[No Abstract] [Full Text] [Related]
6. Thalidomide and dexamethasone: a new standard of care for initial therapy in multiple myeloma.
Richardson P; Anderson K
J Clin Oncol; 2006 Jan; 24(3):334-6. PubMed ID: 16365174
[No Abstract] [Full Text] [Related]
7. Successful treatment of multiple myeloma--associated amyloidosis by interferon-alpha, dimethyl sulfoxide, and VAD (vincristine, adriamycin, and dexamethasone).
Ichida M; Imagawa S; Ohmine K; Komatsu N; Hatake K; Ozawa K; Miura Y
Int J Hematol; 2000 Dec; 72(4):491-3. PubMed ID: 11197218
[TBL] [Abstract][Full Text] [Related]
8. Vincristine, doxorubicin, and dexamethasone or thalidomide plus dexamethasone for newly diagnosed patients with multiple myeloma?
Jimenez-Zepeda VH; Domínguez-Martínez VJ
Eur J Haematol; 2006 Sep; 77(3):239-44. PubMed ID: 16856924
[TBL] [Abstract][Full Text] [Related]
9. High dose simvastatin does not reverse resistance to vincristine, adriamycin, and dexamethasone (VAD) in myeloma.
van der Spek E; Bloem AC; Sinnige HA; Lokhorst HM
Haematologica; 2007 Dec; 92(12):e130-1. PubMed ID: 18055977
[TBL] [Abstract][Full Text] [Related]
10. Is double autologous stem-cell transplantation appropriate for new multiple myeloma patients?
van Rhee F
Nat Clin Pract Oncol; 2008 Feb; 5(2):70-1. PubMed ID: 17984985
[No Abstract] [Full Text] [Related]
11. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for the development of bacterial infections in multiple myeloma treated with two different vincristine-adriamycin-dexamethasone schedules.
Cesana C; Nosari AM; Klersy C; Miqueleiz S; Rossi V; Ferrando P; Valentini M; Barbarano L; Morra E
Haematologica; 2003 Sep; 88(9):1022-8. PubMed ID: 12969810
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of refractory multiple myeloma with vincristine, adriamycin, and dexamethasone].
Ma MX; Yiu JR; Wu SL
Zhonghua Nei Ke Za Zhi; 1989 May; 28(5):267-9, 313. PubMed ID: 2805963
[TBL] [Abstract][Full Text] [Related]
14. Oral idarubicin, dexamethasone and vincristine in the treatment of multiple myeloma: final analysis of a phase II trial.
Glasmacher A; Goldschmidt H; Mezger J; Haferlach T; Schmidt-Wolf IG; Gieseler F;
Haematologica; 2004 Mar; 89(3):371-3. PubMed ID: 15020285
[TBL] [Abstract][Full Text] [Related]
15. High dose dexamethasone as first line therapy of multiple myeloma? A case report.
Meregalli M; Bertola G; Grando D
Recenti Prog Med; 1998 Jan; 89(1):18-20. PubMed ID: 9549388
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib in multiple myeloma: treatment and retreatment. A single center experience.
Warzocha K; Kraj M; Pogłód R; Kwaśniak B
Acta Pol Pharm; 2008; 65(6):753-6. PubMed ID: 19172860
[No Abstract] [Full Text] [Related]
17. Refractory multiple myeloma treated with homoharringtonine: report of two cases.
Yang X; Yang C; Shao K; Ye X; Meng H; Zhou Y; Qian W
Ann Hematol; 2007 Dec; 86(12):919-21. PubMed ID: 17641891
[No Abstract] [Full Text] [Related]
18. [Rheumatoid arthritis and multiple myeloma--the risk of a combination of the 2 diseases].
Lila AM; Mazurov VI; Novik AA
Ter Arkh; 1997; 69(2):50-2. PubMed ID: 9173578
[No Abstract] [Full Text] [Related]
19. Distinct patterns of chromonychia, Beau's lines, and melanoderma seen with vincristine, adriamycin, dexamethasone therapy for multiple myeloma.
Dasanu CA; Vaillant JG; Alexandrescu DT
Dermatol Online J; 2006 Oct; 12(6):10. PubMed ID: 17083890
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of liposomal doxorubicin, vincristine and dexamethasone in multiple myeloma.
Hönemann D; Prince HM; Seymour JF; Wolf MM; Westerman D; Januszewicz EH
Leuk Lymphoma; 2005 Jun; 46(6):945-7. PubMed ID: 16019544
[No Abstract] [Full Text] [Related]
[Next] [New Search]
